Skip to main content
Log in

Bacterial resistance surveillance in China: a report from Mohnarin 2004–2005

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of this study was to establish a nationwide antimicrobial resistant surveillance network and obtain information on bacterial resistance in China. A total of 4075 clinical bacterial isolates were collected from 17 hospitals in 15 cities throughout China. Antibacterial minimal inhibitory concentrations (MICs) were determined by the standard agar dilution method recommended by Clinical and Laboratory Standards Institute. The results of the MICs revealed the following bacterial resistance characteristics. Oxacillin resistance was shown by 62.9% of Staphylococcus aureus and 82.89% of Staphylococcus epidermidis strains. Penicillin non-sensitivity was show by 40.7% of the Streptococcus pneumoniae strains, which included 10.5% penicillin-resistant strains and 30.2% penicillin-intermediate strains. Five strains of Enterococci were vancomycin-intermediate, but all Enterococci strains were sensitive to teicoplanin. All Staphylococci were susceptible to glycopeptides. A high resistance to macrolides was a predominant characteristic of the Gram-positive cocci. Enterobacteriaceae strains were clearly resistant to the third generation cephalosporins, with the exception of ceftazidime, and the resistance rates ranged from 20 to 70%. About 65% of the Escherichia coli strains were resistant to fluoroquinolones. Carbapenems remained highly active against all the target bacteria. Latamoxef, piperacillin/tazobactam, cefoperazone/sulbactam and cefepime were all active against Enterobacteriaceae, which showed resistant rates of less than 10%. Imipenem resistance was found in 10.6% of Pseudomonas aeruginosa and 10.4% of Acinetobacter baumannii strains, most of which were multidrug resistant isolates. Combinations of β-lactam/β-lactamase inhibitor and fluoroquinolones also had potent antibacterial activity against non-fermenters. Amikacin was active against Enterobacteriaceae and P. aeruginosa. In conclusion, methicillin-resistant Staphylococci, penicillin-insensitive S. pneumoniae, macrolides-resistant Gram-positive cocci, cephalosporin-resistant Enterobacteriaceae, multidrug-resistant nonfermenters and fluoroquinolone-resistant E. coli were revealed to be the most serious problems in terms of bacteria resistance in China. No glycopeptides-resistant Staphylococcus strains were isolated, and the appearance of glycopeptides-resistant Enterococci was seldom.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yang LP, Li L, Xiao J (2006) Analysis of drug use in 16 hospitals of Chengdu area during 2000–2004. Evaluation Analysis Drug-Use Hospital China 6:284–286

    CAS  Google Scholar 

  2. National Committee for Clinical Laboratory Standards, 6th edn (1997) Methods for dilution antimicrobial susceptible tests for bacteria that grow aerobically. NCCLS approved document M7-A6. NCCLS, Villanova

  3. Li CR, Li Y, Zhang PA (2003) Dissemination and spread of CTX-M extended-spectrum β-lactamases among clinical isolates of Klebsiella pneumoniae in central China. Int J Antimicrob Agents 22:521–525

    Article  PubMed  CAS  Google Scholar 

  4. Munday CJ, Xiong J, Li C et al. (2004) Dissemination of CTX-M type beta-lactamases in Enterobacteriaceae isolates in the People’s Republic of China. Int J Antimicrob Agents 3:175–180

    Article  Google Scholar 

  5. Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41:S120–126

    Article  PubMed  CAS  Google Scholar 

  6. Robicsek A, Jacoby GA, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6:629–640

    Article  PubMed  CAS  Google Scholar 

  7. Fedler KA, Biedenbach DJ, Jones RN (2006) Assessment of pathogen frequency and resistance patterns among pediatric isolates: report from the 2004 SENTRY antimicrobial surveillance program on 3 continents. Diag Microbiol Infect Dis 56:427–436

    Article  CAS  Google Scholar 

  8. Li JT, Li Y, Wang J (2003) Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections. Chinese Natl J Med 83:265–275

    Google Scholar 

  9. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN (2003) The Alexander project 1998- 2000: susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52:229–246

    Article  PubMed  CAS  Google Scholar 

  10. Jenkins SG, Brown SD, Farrell DJ (2008) Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the US: update from PROTEKT US years 1–4. Ann Clin Microbiol Antimicrob 7:1–36

    Article  PubMed  Google Scholar 

  11. Bozdogan B, Bogdanovich T, Kosowska K, Jacobs MR, Appelbaum PC (2004) Macrolide resistance in Streptococcus pneumoniae: clonality and mechanisms of resistance in 24 countries. Curr Drug Targets Infect Disord 4:169–176

    Article  PubMed  CAS  Google Scholar 

  12. Song JH, Chang HH, Suh JY, Ko KS, Jung SI, Oh WS et al (2004) Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother. 53:457–463

    Article  PubMed  CAS  Google Scholar 

  13. Yao C, Yu ZB, Xiao YH (2005) Study on drug resistance and molecular epidemiology of Streptococcus pneumoniae isolated in Chongqing. Chinese J Epidemiol 26:431–434

    Google Scholar 

  14. Jones RN (2003) Global Epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997–2001). Semin Respir Crit Care Med 24:121–134

    Article  PubMed  Google Scholar 

  15. Sader HS, Fritsche TR, Jones RN (2005) Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY antimicrobial surveillance program (1998–2003). Diag Microb Infect Dis 52:265–273

    Article  Google Scholar 

  16. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y et al (2005) Regional variation in the prevalence of extended-spectrum β-lactamase–producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diag Microb Infect Dis 52:323–329

    Article  Google Scholar 

  17. Serhat U, Robert M, Herman G (2004) Bacteraemia in Europe—antimicrobial susceptibility data from the MYSTIC surveillance program. Int J Antimicrobial Agents 23:155–163

    Article  Google Scholar 

  18. Louis BR (2006) Antimicrobial resistance in Gram-positive bacteria. Am J Med 119:S11–S19

    Google Scholar 

  19. Li JT, Qi HM, Li Y (2005) 2002–2003 Bacterial resistance surveillance on Gram-positive cocci isolated from hospital acquired infections and community acquired infections in China. Chinese J Lab Med 28:254–265

    CAS  Google Scholar 

  20. Li JT, Weinstein AJ, Yang M (2001) Surveillance of bacterial resistance in China (1998–1999). Chinese Natl J Med 81:8–16

    CAS  Google Scholar 

  21. Li JT, Li Y, Wang J (2003) Surveillance on drug resistance of gram-negative bacilli isolated from hospital acquired infections and community acquired infections (2000∼2001). Chinese Natl J Med 83:1035–1045

    Google Scholar 

  22. Li JT, Li Y, Qi HM (2005) 2002–2003 Bacterial resistance surveillance study on Gram-negative bacilli in China. Chinese J Lab Med 28:19–29

    CAS  Google Scholar 

  23. Zhu DM, Wang F, Zhang YY (2005) Surveillance of bacterial resistance from hospitals in Shanghai in 2003. Chinese J Infection Chemotherapy 5:4–12

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Y. H. Xiao.

Additional information

Participants in the Mohnarin surveillance program

Member hospitals and participants of Mohnarin: Peking University First Hospital Institute of Clinical Pharmacology (Yonghong Xiao, Jin Wang, Yun Li, Jian Liu, Feng Xue, Wei Zhong, Fenglan Hao, Weiwei Yang and Huimin Qi), Beijing Hospital (Xiuzheng Zhang and Yunjian Hu), Jilin University First Hospital (Jiancheng Xu and Jin Huang), Chinese Medical University First Hospital (Yunzhuo Chu and Qian Wang), Tianjin Medical University First Hospital (Zhidong Hu and Bin Tian), Hebei Medical University Second Hospital (Jingfang Yang and Xing Wang ), Jiangsu People’s Hospital (Wangshen Zhao and Genyan Liu), Fudan University Zhongshan Hospital (Bijie Hu and Chunmei Zhou), Zhejiang University First Hospital (Yunsong Yu and Haishen Kong HS), Zhongshan University Third Hospital (Yingchun Tang and Yun Xi), Shenzhen People’s Hospital (Jian Yang and Weiyuan Wei), Wuhan University People’s Hospital (Yan Li and Jinling Shi), Zhongnan University Xiangya Hospital (Yin Tang and Mingxiang Zou), Sichuan University West China Hospital (Xiaoju Lv and Hong Fan), Chengdu Pediatric Hospital (Yajing Yang and Li Zhang), Third Military Medical University Southwest Hospital (Weilin Fu and Xiaobing Zhang), Fourth Military Medical University Xijing Hospital (Xiuli Xu and Yiqun Sun).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiao, Y.H., Wang, J., Li, Y. et al. Bacterial resistance surveillance in China: a report from Mohnarin 2004–2005. Eur J Clin Microbiol Infect Dis 27, 697–708 (2008). https://doi.org/10.1007/s10096-008-0494-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0494-6

Keywords

Navigation